急性髓系白血病(acute myeloid leukemia,AML)是一组高度异质性的克隆性疾病,获得性体细胞突变在造血干祖细胞中不断累积是其主要的发病基础,AML约占白血病的85%, 在成年白血病患者中发病率最高,预后不良,五年相对存活率仅为 17-19%。 AML临床主要表现为贫血、出血、发热、感染,该病多具有病情急重、难以控制、容易...
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an incidence of over 20 000 cases per year in the United States alone. Large chromosomal translocations as well as mutations in the genes involved in hematopoietic prolifer
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhi
急性髓系白血病(Acute myeloid leukemia, AML)是一种以髓系祖细胞克隆扩增和分化阻滞为特征的骨髓恶性疾病【1】。其具有高遗传异质性和复杂的克隆进化特征【2】。AML是成人急性白血病中最常见的一种形式,生存期最短 (5年生存期仅 24%)。包括强化化疗和异基因干细胞移植在内的治疗性治疗通常适用于少数年轻和健康的...
CBF 急性髓系白血病的英文名字是CBF acute myeloid leukemia。基因解码表明:急性髓系白血病(CBF-AML)通常是由基因突变引起的。CBF-AML是一种白血病亚型,其特征是两个基因的染色体易位或重排。这些基因包括RUNX1-RUNX1T1(t(8;21))和CBFB-MYH11(inv(16)或t(16;16))。这些基因突变导致造血干细胞的异常增殖和...
Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML), complete remission is currently still considered the gold standard of care. A Germany-wide clinical trial now shows for the first time that this approach does not benefit disease-free survival or overal...
Related to acute myeloid leukemia:Chronic Myeloid Leukemia ThesaurusAntonymsRelated WordsSynonymsLegend: Switch tonew thesaurus Noun1. acute myeloid leukemia- acute leukemia characterized by proliferation of granular leukocytes; most common in adolescents and young adults ...
Patients 4,6,9, and 1 relapsed after achieving 1,8,10, and 16 months of relapse-free survival, respectively. The pattern of relapse in patient 4 (testicular followed by ocular and then hematologic) was unusual for myeloid leukemia; however, this patient did not respond to vincristine, ...
The acute myeloid leukemia treatment market size was valued at USD 3.8 billion in 2023, driven by the increasing emphasis on providing personalized treatment for cancer patients. The market size is anticipated to grow at a CAGR of 9.8% during the forecast period of 2024-2032 to achieve a value...
Primary or “de novo” AML refers to myeloid leukemia arising in the absence of an antecedent myeloid neoplasm, without a mutational pattern strongly linked with sAML, and without prior exposure to leukemogenic therapies. From: Clinics in Laboratory Medicine, 2022 ...